Health experts want FDA safety review of fast-tracked Alzheimer’s drug
Jason Karlawish of the Perelman School of Medicine says that an independent panel needs to meet to discuss the use of beta amyloid PET scans to support a drug’s accelerated approval.
・ From Axios